S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:BLUE

bluebird bio (BLUE) Stock Forecast, Price & News

$3.57
+0.20 (+5.93%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$3.38
$3.63
50-Day Range
$3.21
$5.23
52-Week Range
$3.11
$35.59
Volume
2.21 million shs
Average Volume
2.35 million shs
Market Capitalization
$255.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.63
30 days | 90 days | 365 days | Advanced Chart
Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

bluebird bio logo

About bluebird bio

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLUE
Fax
N/A
Employees
518
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.66 million
Book Value
$3.68 per share

Profitability

Net Income
$-819.38 million
Net Margins
-2,183.15%
Pretax Margin
-1,670.90%

Debt

Price-To-Earnings

Miscellaneous

Free Float
69,382,000
Market Cap
$255.09 million
Optionable
Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/16/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.38 out of 5 stars

Medical Sector

213th out of 1,403 stocks

Biological Products, Except Diagnostic Industry

30th out of 206 stocks

Analyst Opinion: 4.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -













bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

Is bluebird bio a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 11 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" bluebird bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View analyst ratings for bluebird bio
or view top-rated stocks.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for bluebird bio
.

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) issued its earnings results on Monday, May, 9th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by $0.10. The biotechnology company had revenue of $1.95 million for the quarter, compared to the consensus estimate of $0.17 million. bluebird bio had a negative net margin of 2,183.15% and a negative trailing twelve-month return on equity of 111.73%. The business's revenue for the quarter was up 117.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($3.07) earnings per share.
View bluebird bio's earnings history
.

What price target have analysts set for BLUE?

15 equities research analysts have issued 12 month target prices for bluebird bio's stock. Their forecasts range from $3.00 to $23.00. On average, they anticipate bluebird bio's stock price to reach $11.92 in the next year. This suggests a possible upside of 233.8% from the stock's current price.
View analysts' price targets for bluebird bio
or view top-rated stocks among Wall Street analysts.

Who are bluebird bio's key executives?
bluebird bio's management team includes the following people:
  • Mr. Andrew Obenshain, Pres, CEO & Director (Age 47) (LinkedIn Profile)
  • Mr. Jason F. Cole Esq., Chief Strategy & Financial Officer (Age 49, Pay $619.8k)
  • Mr. Kasra Kasraian, Sr. VP of Technical Devel. & Operations
  • Ms. Jessica Whitten, VP, Global Controller & Chief Accounting Officer (Age 45) (LinkedIn Profile)
  • Ms. Elizabeth Pingpank, Director of Corp. Communications
  • Sarah Alspach, Chief Communications Officer
  • Ms. Kathleen A. Wilkinson, Chief People Officer (Age 50)
  • Dr. Liviu Niculescu M.D., Ph.D., Sr. VP of Global Medical Affairs
  • Ms. Melissa Bonner, Sr. VP of Research
  • Ms. Anne-Virginie Eggimann M.Sc., Chief Regulatory Officer
What is Nick Leschly's approval rating as bluebird bio's CEO?

66 employees have rated bluebird bio CEO Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among bluebird bio's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), (CELG), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.30%), BlackRock Inc. (8.17%), JPMorgan Chase & Co. (2.61%), Renaissance Technologies LLC (1.32%), Federated Hermes Inc. (1.28%) and Northern Trust Corp (0.98%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Andrew Obenshain, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly and William D Baird III.
View institutional ownership trends for bluebird bio
.

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., Citigroup Inc., Principal Financial Group Inc., Group One Trading L.P., BlackRock Inc., Mirae Asset Global Investments Co. Ltd., and Russell Investments Group Ltd.. Company insiders that have sold bluebird bio company stock in the last year include Andrew Obenshain, Jason Cole, Jessica Whitten, and Nick Leschly.
View insider buying and selling activity for bluebird bio
or view top insider-selling stocks.

Which major investors are buying bluebird bio stock?

BLUE stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Federated Hermes Inc., Healthcare of Ontario Pension Plan Trust Fund, Dimensional Fund Advisors LP, Capital Fund Management S.A., Qube Research & Technologies Ltd, Ergoteles LLC, and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for bluebird bio
or or view top insider-buying stocks.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $3.57.

How much money does bluebird bio make?

bluebird bio has a market capitalization of $255.09 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819.38 million in net income (profit) each year or ($10.54) on an earnings per share basis.

How many employees does bluebird bio have?

bluebird bio employs 518 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (339) 499-9300 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.